Forecast and Trend Analysis on Global Orphan Drugs Market 2016 Edition

A rare disease is the one that occurs uncommonly or rarely in the general population. However, there exists no clear definition for categorizing “rare diseases” and is usually defined on the basis of the prevalence, and some other factors including the severity of disease and availability of treatment options. Rare diseases are often serious, chronic and progressive. Orphan drugs are medicinal products intended for the diagnosis, prevention or treatment of rare diseases. These drugs are referred to be “orphan” as under normal conditions because these drugs are not cost effective to be developed by the pharmaceuticals industry, intended for a small number of patients suffering from rare conditions.

Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/58643 .

Increasing sales of prescription drugs, substantial benefits for new entrants in rare disease drug market, increased spending on medicines, rising healthcare expenditure and improving economic conditions of nations are some of the significant factors driving growth of the Orphan drugs market. However, the growth of the market is hindered by certain challenges including tougher regulatory approvals, limitation on charging higher prices and no approved drugs for several rare diseases including Polychethemia Vera (PV).

Purchase a copy of Global Orphan drugs Market visit @ http://www.orbisresearch.com/contact/purchase/58643  For more information contact sales@orbisresearch.com .

The global orphan drugs market is expected to see numerous developments including approval of several Ultra-Rare drugs, increasing scope of Gene therapy, development of drugs for rare blood disease, higher success prospects for Hematology compared to Solid Tumors, attractive pricing option for orphan drug competitors and striking opportunities in developing orphan drugs.

The report, “Global Orphan Drugs Market” analyzes the current prevailing condition of the market along with its future scope of development. The global market along with specific market of the U.S., Canada, Europe and Japan, is being discussed in the report. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The major players in the industry are being profiled, along with their key financials and strategies for growth.

Browse Complete Report @ http://www.orbisresearch.com/reports/index/global-orphan-drugs-market-report-2016-edition .

Some points from TOC:

1. Orphan Diseases: Introduction
1.1 Causes
1.2 Prevention
1.3 Diagnosis
1.4 Treatment Options
1.5 Orphan Drugs

2. Market Analysis
2.1 Global Orphan Drugs Market
-Market Value
-Growth Rate
-Market Segmentation
2.1.1 Non-Hodgkin’s Lymphoma (NHL) Market

3. Regional Analysis
3.1 The U.S. Orphan Drugs Market
- Applications & Designations
-Spending Growth Forecast
3.1.1 The Ultra-Rare Drugs Market
3.2 Canada
3.3 Europe
3.4 Japan

4. Market Dynamics
4.1 Key Trends and Developments
4.1.1 Striking Opportunities in Developing Orphan Drugs
4.1.2 Attractive Pricing Option for Orphan Drug Companies
4.1.3 Higher Success Prospect for Hematology vs. Solid Tumors
4.1.4 Development of Drugs for Rare Blood Diseases
4.1.5 Increasing Scope of Gene Therapy
4.1.6 Approval of Ultra-Orphan Drugs
4.2 Growth Drivers
4.2.1 Increasing Sales of Prescription Drugs
4.2.2 Substantial Benefits for New Entrants in Rare Diseases Market
4.2.3 Increased Spending on Medicines
4.2.4 Rising Healthcare Expenditure
4.2.5 Rising Global GDP
4.3 Challenges
4.3.1 Limitation on Charging High Price for Orphan Drugs
4.3.2 No Approved Drug for Polycythemia Vera First-line Treatment
4.3.3 Tough Regulatory Approval for Orphan Drugs

For any enquires before buying, connect with us @ enquiry@orbisresearch.com